Explore 3 Stock Ideas & Industry Insights Download Free Report

News

What Did a USD 389.7 Million Charge Do to Liquidia (NASDAQ:LQDA) as Opus Genetics (NASDAQ:IRD), Kalaris Therapeutics (NASDAQ:KLRS) and Kura Oncology (NASDAQ:KURA) Reported?

Key HighlightsLiquidia (NASDAQ:LQDA) booked a USD 389.7 million litigation settlement charge that turned USD 222.7 million of product sales into aGAAPnet loss of USD 236.3 million.Opus Genetics (NASDAQ:IRD) lost USD 46.5 million, of which USD 28.6 million was a non-cashFair Valuecharge on warrants and …

Vinay Lochav | 12 November 2026

Can USD 798.4 Million Take Veradermics (NYSE:MANE) to 2030 While Metagenomi Therapeutics (NASDAQ:MGX), NextCure (NASDAQ:NXTC) and Olema Pharmaceuticals (NASDAQ:OLMA) Count Their Cash?

Key HighlightsVeradermics (NYSE:MANE) held USD 798.4 million in cash, equivalents and marketable securities, which management believes funds operating expenses andCapitalneeds into 2030.Metagenomi Therapeutics (NASDAQ:MGX) reported collaborationRevenueof USD 2.18 million against USD 8.66 million a year earlier, and the FDA cleared its MGX-001 application in …

Vinay Lochav | 12 November 2026

Is a 659% R&D Jump Affordable at Palisade Bio (NASDAQ:PALI), and How Do Ovid Therapeutics (NASDAQ:OVID), Passage Bio (NASDAQ:PASG) and PepGen (NASDAQ:PEPG) Compare?

Key HighlightsPalisade Bio (NASDAQ:PALI) reportedResearch and Developmentexpense up 659% to USD 10.6 million, with cash of USD 113.6 million that management believes funds operations through both Phase 2 readouts.Ovid Therapeutics (NASDAQ:OVID) lost USD 20.8 million against USD 12.2 million and held USD 161.4 million, …

Vinay Lochav | 12 November 2026

How Do a 46% Layoff at Sionna Therapeutics (NASDAQ:SION) and the Cash Positions of PMV Pharmaceuticals (NASDAQ:PMVP), PolyPid (NASDAQ:PYPD) and Protalix BioTherapeutics (NYSEAMERICAN:PLX) Compare?

Key HighlightsSionna Therapeutics (NASDAQ:SION) held USD 249.8 million at September 30, 2026 after cutting about 46% of its workforce, and says that cash funds operations into the second half of 2029.PMV Pharmaceuticals (NASDAQ:PMVP) cut operating expenses to USD 20.1 million from USD 22.5 million, …

Vinay Lochav | 12 November 2026

Can Cash Last Through 2030 at Tyra Biosciences (NASDAQ:TYRA), and How Do Upstream Bio (NASDAQ:UPB), Xilio Therapeutics (NASDAQ:XLO) and Scholar Rock (NASDAQ:SRRK) Compare?

Key HighlightsTyra Biosciences (NASDAQ:TYRA) held USD 700.5 million at September 30, 2026, which it says funds operating expenses and capital expenditures through 2030, while its third-quarter net loss rose to USD 51.1 million.Upstream Bio (NASDAQ:UPB) held USD 207.4 million, which it says funds operations …

Vinay Lochav | 12 November 2026

How Can Cash Range From USD 8.7 Million at Bionano Genomics (NASDAQ:BNGO) to USD 236.3 Million at Anteris Technologies Global (NASDAQ:AVR), Carlsmed (NASDAQ:CARL) and Electromed (NYSEAMERICAN:ELMD)?

Key HighlightsAnteris Technologies Global (NASDAQ:AVR) held USD 236.3 million of cash and restricted cash at September 30, 2026 against a third-quarter net loss of USD 26.8 million.Bionano Genomics (NASDAQ:BNGO) ended the quarter with USD 8.7 million of cash, cash equivalents and securities, and the …

Vinay Lochav | 12 November 2026

What Is Behind USD 60.1 Million of Net Income at Freenome (NASDAQ:FRNM) and USD 7.2 Million at Lumexa Imaging (NASDAQ:LMRI), and How Do KORU Medical Systems (NASDAQ:KRMD) and Intelligent Bio Solutions (NASDAQ:INBS) Compare?

Key HighlightsFreenome (NASDAQ:FRNM) reported third-quarterGAAPNet Incomeof USD 60.1 million against a USD 64.5 million loss, after USD 180.0 million was recognized under its license agreement following FDA approval of SimpleScreen CRC.Lumexa Imaging (NASDAQ:LMRI) swung to net income of USD 7.2 million from a USD …

Vinay Lochav | 12 November 2026

How Are Precipio (NASDAQ:PRPO) After a USD 8,000 Loss, Orchestra BioMed (NASDAQ:OBIO) After a USD 80.5 Million Raise, LENSAR (NASDAQ:LNSR) and QT Imaging Holdings (NASDAQ:QTI) Managing Thin Cash?

Key HighlightsPrecipio (NASDAQ:PRPO) cut its third-quarter net loss to USD 8,000 from USD 79,000 on net sales of USD 7.3 million, while its filing saysGoing Concernstatus depends on achieving its plan.Orchestra BioMed (NASDAQ:OBIO) closed an offering of 17,250,000 shares at USD 5.00 on November …

Vinay Lochav | 12 November 2026

Why Did System Sales Drop 73% at SANUWAVE Health (NASDAQ:SNWV) While Seer (NASDAQ:SEER), Sonoma Pharmaceuticals (NASDAQ:SNOA) and Stereotaxis (NYSEAMERICAN:STXS) Diverged?

Key HighlightsSANUWAVE Health (NASDAQ:SNWV) reported UltraMIST systemRevenuedown about 73% to USD 1.2 million, dragging third quarter revenue down 24% to USD 8.579 million.Seer (NASDAQ:SEER) lowered 2026 revenue guidance to USD 13.5 million to 14.5 million from USD 16 million to 18 million after third …

Vinay Lochav | 12 November 2026

Is 14 Straight Quarters of Price Gains at Exagen (NASDAQ:XGN) Enough as TELA Bio (NASDAQ:TELA), TriSalus Life Sciences (NASDAQ:TLSI) and Harvard Bioscience (NASDAQ:HBIO) Report Mixed Results?

Key HighlightsExagen (NASDAQ:XGN) reported a record trailing 12-month average selling price of USD 451 per AVISE CTD test, the 14th consecutive quarterly improvement, onRevenueof USD 18.4 million.TELA Bio (NASDAQ:TELA) cut its adjusted EBITDA loss 40% to USD 3.4 million while revenue fell 8% to …

Vinay Lochav | 12 November 2026
Support

Hi! How can we help you today?

Loading…